Connor Iapoce is an assistant editor for HCPLive and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at firstname.lastname@example.org.
Ty Gluckman, MD speaks on the use of medical technology, including wearables and and telemedicine, and the growing importance of mobile health.
The progress of innovations in the cardiovascular care space, particularly wearables and access to telemedicine, grew in importance during the COVID-19 pandemic and perhaps even the environment that has followed.
As part of this larger conversation, Ty Gluckman, MD, Medical Director, Center for Cardiovascular Analytics, Research, and Data Science at Providence St. Joseph Health, moderated “Practical Strategies in Practice” at the American Society for Preventive Cardiology’s 2021 Virtual Summit on CVD Prevention.
In an interview with HCPLive, Gluckman spoke on the importance and recognition of clinicians that as they shift into population health, the ability to collect information from patients to inform care delivery might have particular importance.
“The pandemic hit and many of us had to morph, having never done a telehealth virtual visit into that world, and remote patient monitoring and virtual care delivery became that much more important,” Gluckman said. “In light of the pandemic, and the landscape that has followed, the devices that we rely upon historically, will only grow in their importance and increasingly mobile health, virtual care delivery, telemedicine will become a key driver for us in the years to come.”
However, he noted the limits of advances in medicine technology, observing that the technological advances have outstripped understanding of what they can do with the information, noting a study done on the Apple Watch in accurately identifying atrial fibrillation.
“The ability to have technology that is moving faster than we know what to do with it, the trials, and the data that comes out allows us to understand how it should be operationalized,” Gluckman said. "I think that's a cycle that will persist. But having that information done in a more rigorous fashion, will allow us for boots on the ground clinicians to understand how to utilize the technology.”